TY - JOUR
T1 - Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study
T2 - a substudy of ACTFAST.
AU - Blanco-Colio, Luis M.
AU - Martín-Ventura, Jose L.
AU - de Teresa, Eduardo
AU - Farsang, Csaba
AU - Gaw, Allan
AU - Gensini, Gianfranco
AU - Leiter, Lawrence A.
AU - Langer, Anatoly
AU - Martineau, Pierre
AU - Egido, Jesús
PY - 2008/12
Y1 - 2008/12
N2 - The CD40/CD40 ligand plays a role in the inflammatory and prothrombotic processes in atherosclerosis. We analyzed whether short-term treatment with atorvastatin affects soluble CD40 ligand (sCD40L) plasma levels in subjects at high cardiovascular risk. sCD40L plasma concentrations were measured in 852 subjects from the Atorvastatin on Inflammatory Markers (AIM) Study, a 12-week prospective multicenter, open-label trial which enrolled statin-free subjects with coronary heart disease (CHD), CHD-equivalent (diabetes, peripheral vascular disease, or cerebrovascular disease), or a 10-year CHD risk >20%. Subjects were assigned to atorvastatin (10-80 mg/day) based on LDL-C at screening. Overall, sCD40L levels were not different in patients at high cardiovascular risk compared with healthy subjects. When sCD40L levels were divided in quartiles, patients in the highest quartile (N=213) had higher sCD40L concentrations than age- and gender-matched healthy subjects (N=29) (P
AB - The CD40/CD40 ligand plays a role in the inflammatory and prothrombotic processes in atherosclerosis. We analyzed whether short-term treatment with atorvastatin affects soluble CD40 ligand (sCD40L) plasma levels in subjects at high cardiovascular risk. sCD40L plasma concentrations were measured in 852 subjects from the Atorvastatin on Inflammatory Markers (AIM) Study, a 12-week prospective multicenter, open-label trial which enrolled statin-free subjects with coronary heart disease (CHD), CHD-equivalent (diabetes, peripheral vascular disease, or cerebrovascular disease), or a 10-year CHD risk >20%. Subjects were assigned to atorvastatin (10-80 mg/day) based on LDL-C at screening. Overall, sCD40L levels were not different in patients at high cardiovascular risk compared with healthy subjects. When sCD40L levels were divided in quartiles, patients in the highest quartile (N=213) had higher sCD40L concentrations than age- and gender-matched healthy subjects (N=29) (P
UR - http://www.scopus.com/inward/record.url?scp=61549117198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=61549117198&partnerID=8YFLogxK
M3 - Article
C2 - 19034329
AN - SCOPUS:61549117198
JO - Kidney International, Supplement
JF - Kidney International, Supplement
SN - 0098-6577
IS - 111
ER -